SIRT3

SIRT3

A gene on chromosome 11p15.5 that encodes a widely expressed NAD-dependent enzyme that deacetylates key lysine residues, activating mitochondrial target proteins (e.g., ACSS1, IDH2 and GDH), thereby playing a role in cellular energy metabolism by regulating tissue-specific ATP levels.
References in periodicals archive ?
The mitochondria contain three of the seven mammalian sirtuins, including SIRT3 and SIRT4.
The SIRT3 gene encodes a protein also called SIRT3.
Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle.
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome.
It was discovered that SIRT3, a mitochondrial deacetylase, represses cellular glycolysis through the regulation of HIF1alpha, a transcription factor that increases gene expression of glycolytic targets.
Ethanol-induced suppression of SIRT3 and the concomitant increase of another acetylation pathway (i.
The biologists found that SIRT3, one among a class of proteins known as sirtuins, plays an important role in helping aged blood stem cells cope with stress.
A study by Sirtris Scientific Advisory Board members and Harvard University scientists, published in the journal Cell in September 2007, showed for the first time that activation of SIRT3 and SIRT4 protects against cell damage.
9,17,18) Sirtuins, specifically SIRT1 and SIRT3, are intimately related to longevity through their control of gene expression and require NAD+ for their activity.
2007; Feng and Forgac 1992); and HNE adduct formation at Cys280 inhibits mitochondrial SIRT3 (SIRT3) activity (Fritz et al.
Previous studies indicated that two other members of the sirtuin family - SIRT1 and SIRT3 - have tumour suppressor functions.
Such statements include, but are not limited to, the potential therapeutic effects of SIRT1 activators for diseases of aging, such as Type 2 Diabetes, cancer, and other disorders; the potential effects of SIRT3 activators for metabolic diseases; the progress and potential results of pre-clinical and clinical studies of SRT501 and novel chemical entities; the initiation of additional clinical trials to test the potential therapeutic effects of SIRT1 activators; the possibility of a strategic partnership within the next 12-18 months; and the potential of sirtuin activators to receive regulatory approval.